Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01969266 · ClinicalTrials.gov registry record · Phase 1

A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food

A Phase 1 study, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target

NCT01969266: Completed Phase 1 study, sponsored by Janssen Research & Development.

NCT01969266 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01969266, a Phase 1 study, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target

Study Summary

The purpose of this study is to examine the exposure and safety of a supratherapeutic dose of PCI-32765 (ibrutinib) in healthy adult volunteers.

Interventions

  • DRUG Treatment A: PCI-32765
  • DRUG Treatment B: PCI-32765

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2013-10
Est. Completion 2013-11
Phase Phase 1
Janssen Research & Development

593 total trials

What the finished NCT01969266 record still lists

NCT01969266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).

The record links to 0 conditions, and to 2 interventions - of which Treatment A: PCI-32765 is the first listed.

NCT01969266 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01969266 about?

NCT01969266 is a clinical study titled "A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food". The purpose of this study is to examine the exposure and safety of a supratherapeutic dose of PCI-32765 (ibrutinib) in healthy adult volunteers.

What is the current status of trial NCT01969266?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-10. Estimated completion is 2013-11.

What interventions are being tested in trial NCT01969266?

The interventions under investigation include: Treatment A: PCI-32765 (DRUG), Treatment B: PCI-32765 (DRUG).

Who is sponsoring clinical trial NCT01969266?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01969266's enrollment target sits among peer trials

8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01969266, the US trial registry maintained by the National Library of Medicine. NCT01969266 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.